Table 1 Anti-malarial drugs for the treatment of uncomplicated malaria in children: practices of health professionals of 7 sub-Saharan- African countries
Anti-malarial | First line treatment | Second line treatment | Third line treatment | |||
|---|---|---|---|---|---|---|
Clinicians Pharmacists | Clinicians Pharmacists | Clinicians | Pharmacists | |||
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Paediatric ACT | ||||||
AL | 25 (61%) | 24 (80%) | 13 (34%) | 12 (43%) | 6 (25%) | 11 (42%) |
AS-AQ | 6 (15%) | 4 (13%) | 11 (29%) | 7 (25%) | 1 (4%) | 3 (12%) |
AS-MQ | ||||||
DHA-PPQ | 2 (5%) | 3 (11%) | 1 (4%) | |||
Total P-ACT | 31 (76%) | 28 (93%) | 26 (68%) | 22 (79%) | 7 (29%) | 15 (58%) |
Tablets ACT | ||||||
AL | 7 (17%) | 2 (7%) | 1 (3%) | 3 (11%) | 2 (8%) | 7 (26%) |
AS-AQ | 3 (7%) | 3 (8%) | 2 (8%) | 1 (4%) | ||
AS-MQ | 2 (8%) | |||||
DHA-PPQ | 2 (5%) | 1 (3%) | 2 (8%) | |||
AS-S/P | 1 (3%) | 2 (7%) | ||||
Total T-ACT | 10 (24%) | 2 (7%) | 7 (18%) | 6 (21%) | 8 (33%) | 8 (30%) |
Suppositories | 1 (3%) | 1 (4%) | ||||
Total ACT | 41 (100%) | 30 (100%) | 34 (89%) | 28 (100%) | 15 (62%) | 24 (92%) |
Paediatric monotherapy | 4 (11%) | 2 (8%) | 1 (4%) | |||
Tablet monotherapy | 5 (20%) | 1 (4%) | ||||
Total non-ACT monotherapy | 4 (11%) | 7 (28%) | 2 (8%) | |||
Total respondents | 41(100%) | 30(100%) | 38(100%) | 28(100%) | 24 (100) | 26(100% |